Diasorin is accelerating US molecular diagnostics and point-of-care positioning, disclosing plans to raise its US molecular market share over the next four years. At an investor day, the company outlined expansion of its Luminex Liaison instrument portfolio and said it shifted molecular test manufacturing to the US. Regulatory progress supported the strategy: Diasorin also received 510(k) clearance for a customizable syndromic GI pathogen PCR panel for its Liaison Plex system. The panel covers 24 pathogens and can be tuned via Flex software for different clinical and stewardship needs, according to the company. Together, the moves show Diasorin leaning into decentralized molecular workflows, emphasizing faster testing and menu expansion across women’s health, STIs, and GI syndromic use cases.